Arno Therapeutics
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company's product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resi… Read more
Arno Therapeutics (ARNI) - Total Liabilities
Latest total liabilities as of September 2016: $8.07 Million USD
Based on the latest financial reports, Arno Therapeutics (ARNI) has total liabilities worth $8.07 Million USD as of September 2016.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Arno Therapeutics - Total Liabilities Trend (2012–2015)
This chart illustrates how Arno Therapeutics's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Arno Therapeutics Competitors by Total Liabilities
The table below lists competitors of Arno Therapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
France | €1.05 Million |
|
Orchard Funding Group PLC
LSE:ORCH
|
UK | GBX49.90 Million |
|
Spirits Time International Inc
PINK:SRSG
|
USA | $1.60 Million |
|
Amper SA
MU:APR
|
Germany | €297.61 Million |
|
Mix1 Life Inc
PINK:MIXX
|
USA | $8.16 Million |
Liability Composition Analysis (2012–2015)
This chart breaks down Arno Therapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Arno Therapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Arno Therapeutics (2012–2015)
The table below shows the annual total liabilities of Arno Therapeutics from 2012 to 2015.
| Year | Total Liabilities | Change |
|---|---|---|
| 2015-12-31 | $8.99 Million | +69.91% |
| 2014-12-31 | $5.29 Million | -86.58% |
| 2013-12-31 | $39.40 Million | +62.43% |
| 2012-12-31 | $24.26 Million | -- |